Tamoxifen: the drug that came in from the cold.
Despite the perception of many oncologists that tamoxifen is an inferior drug, and should be substituted by an aromatase inhibitor in post-menopausal women, the current evidence strongly supports the view that AIs should be used 2-3 years after tamoxifen to achieve the maximal overall survival (OS) advantage.
Hughes-Davies
L
L
Cambridge Breast Unit, Addenbrooke's Hospital, Hills Road, Cambridge, UK.
Caldas
C
C
Wishart
G C
GC
D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D002986:Clinical Trials as Topic; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D013629:Tamoxifen / Q000627:therapeutic use*
D047072:Aromatase Inhibitors; D004965:Estrogen Antagonists; D013629:Tamoxifen